Senzime AB (publ) announced a supply contract with a top-10 ranked US East Coast-based university hospital system. The contract is the result of a comprehensive clinical and competitive product evaluation and includes TetraGraph monitoring systems for use in pediatric and adult care. The TetraGraph is the first portable electromyography (EMG)-based neuromuscular monitor on the market that is clinically validated and that meets the new clinical guidelines published by the ASA (American Society of Anesthesiologists) and ESAIC (European Society of Anaesthesiology and Intensive Care).

Since market introduction in 2019, the TetraGraph has been installed at hundreds of leading hospitals across the globe. The TetraGraph system is used during surgery to accurately monitor the patient's level of neuromuscular block. This helps anesthesiologists secure the right dose of neuromuscular blocking drugs and their antagonists, as well as indicate when it is safe to allow patients to breathe on their own.

The contract has potential to reach 20,000 patients per year when monitors are in full use. Initial deliveries commence immediately.